The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
Abstract
OBJECTIVE: The authors investigated whether primary negative symptoms of schizophrenia are enduring or treatment-responsive. METHODS: Previously, a double-blind, random-assignment trial of the novel antipsychotic olanzapine (in low, medium, and high dose ranges), placebo, or haloperidol (10-20 mg/day) for 335 schizophrenic inpatients was conducted for up to 52 weeks. Changes in the treatment groups from baseline to endpoint in summary scores on the Scale for the Assessment of Negative Symptoms (SANS) and several secondary measures were compared. This article describes a path analysis to determine to what extent the total treatment effect on negative symptoms was direct or indirect (i.e., mediated by differential effects on positive symptoms, extrapyramidal symptoms, or mood). RESULTS: Significantly greater improvement was achieved with high-dose olanzapine than with placebo or haloperidol. Olanzapine had a significantly greater direct effect than placebo on all SANS dimensions except anhedonia-asociality. Olanzapine also demonstrated a significantly greater direct effect than haloperidol on negative symptoms, especially on the dimensions of affective flattening and avolition-apathy. Olanzapine's superior effects were replicated in a subgroup with SANS-defined prominent negative symptoms (N = 116) and a subgroup with a BPRS-defined cross-sectional proxy for the deficit state (N = 117). CONCLUSIONS: These results suggest that the negative symptoms of schizophrenia are directly responsive to treatment. The significantly greater direct and indirect effects of olanzapine than of haloperidol on negative symptoms are likely related to olanzapine's pleotrophic pharmacology, which includes dopaminergic, serotonergic, muscarinic, and adrenergic activities. The results contribute to the hypothesis that negative symptoms may be under the influence of several neurotransmitters within one or more neuroanatomic circuits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Negative v Positive Schizophrenia: Definition and Validation
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070025006 · Cited by 2,012
Molecular pathology of schizophrenia: more than one disease process?
Crow, T. J. (1980) · BMJ · doi:10.1136/bmj.280.6207.66 · Cited by 1,856
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 778
Symptoms of Schizophrenia: Methods, Meanings, and Mechanisms
Andreasen, N. C. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950170015003 · Cited by 734
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.1.20 · Cited by 388
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1744 · Cited by 382
A Longitudinal Study of Symptom Dimensions in Schizophrenia: Prediction and Patterns of Change
Arndt, S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950170026004 · Cited by 304
Meltzer, H. Y., Bastani, B., Kwon, K. Y., Ramirez, L. F., Burnett, S., & Sharpe, J. (1989) · Psychopharmacology · doi:10.1007/bf00442563 · Cited by 271
Case identification and stability of the deficit syndrome of schizophrenia
Kirkpatrick, B., Buchanan, R. W., Breier, A., & Carpenter, W. T. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90054-k · Cited by 191
Negative and Deficit Symptoms in Schizophrenia Do Respond to Neuroleptics
Goldberg, S. C. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.3.453 · Cited by 174
Statistical Models for Causal Analysis
Retherford, R. D., & Choe, M. K. (1993) · Wiley eBooks · doi:10.1002/9781118033135 · Cited by 168
Structure and Course of Positive and Negative Symptoms in Schizophrenia
Eaton, W. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950140045005 · Cited by 165
Patient response and resource management: another view of clozapine treatment of schizophrenia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.6.827 · Cited by 161
Möller, H., Müller, H., Borison, R. L., Schooler, N. R., & Chouinard, G. (1995) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02191543 · Cited by 147
The Effect of Neuroleptics and Other Psychotropic Drugs on Negative Symptoms in Schizophrenia
Meltzer, H. Y., Sommers, A., & Luchins, D. J. (1986) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198612000-00002 · Cited by 143
A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects
Nyberg, S. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00218-7 · Cited by 135
Pilowsky, L. S., Busatto, G. F., Taylor, M., Sharma, T., Sigmundsson, T., Costa, D. C., Ell, P. J., & Nohria, V. (1996) · Psychopharmacology · doi:10.1007/bf02245615 · Cited by 120
Evaluation of positive and negative symptoms in schizophrenia
Andreasen, N. C., & Grove, W. M. (1986) · Psychiatry and Psychobiology · doi:10.1017/s0767399x00003199 · Cited by 119
Clozapine's effect on negative symptoms in treatment-refractory schizophrenics
Miller, D. D., Perry, P. J., Cadoret, R. J., & Andreasen, N. C. (1994) · Comprehensive Psychiatry · doi:10.1016/0010-440x(94)90164-3 · Cited by 110
Negative symptoms in schizophrenia: a confirmatory factor analysis of competing models
Peralta, V., & Cuesta, M. J. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1450 · Cited by 96
Tandon, R., GOLDMAN, R. S., Goodson, J. A., & Greden, J. F. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90502-s · Cited by 46
Predictors of response to clozapine therapy
Honigfeld, G., & Patin, J. R. (1989) · Psychopharmacology · doi:10.1007/bf00442562 · Cited by 40
Tandon, R., Ribeiro, S. C. M., DeQuardo, J. R., GOLDMAN, R. S., Goodson, J. A., & Greden, J. F. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90242-6 · Cited by 38
Clozapine response varies in deficit vs non-deficit schizophrenic subjects
Conley, R. R., Richardson, C. M., Kent, D., Gounaris, C., & Zaremba, S. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91129-0 · Cited by 29
Psychopharmacologic treatment of negative schizophrenic symptoms
Opler, L. A., Albert, D. B., & RAMIREZ, P. M. (1994) · Comprehensive Psychiatry · doi:10.1016/0010-440x(94)90165-1 · Cited by 22
Drug development and the deficit syndrome of schizophrenia
Kirkpatrick, B. W., & Carpenter, W. T. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)00350-p · Cited by 10
Cited by
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1997-04-01
- Volume
- 154
- Issue
- 4
- Pages
- 466-474
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1638784138
- Cited by
- 305
- References
- 31
- FWCI
- 28.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.